LIGAND PHARMACEUTICALS INC
Q4 2020 13F Holders
CUSIP
53220KAF5
Type
Debt
Class
NOTE 0.750% 5/1
Num filings
49
Total reported value, excl. options
$470 M
Compare 2020 Q4 to
2023 Q2
2023 Q1
2022 Q4
2022 Q3
2022 Q2
2022 Q1
2021 Q4
2021 Q3
2021 Q2
2021 Q1
2020 Q3
2020 Q2
2020 Q1
2019 Q4
2019 Q3
2019 Q2
Manager
Report Date
Value ($000)
Principal
Option Type